Palvella Therapeutics (NASDAQ:PVLA) Director Sells $49,141.00 in Stock

by · The Markets Daily

Palvella Therapeutics, Inc. (NASDAQ:PVLA – Get Free Report) Director Christopher Kiritsy sold 313 shares of Palvella Therapeutics stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $157.00, for a total transaction of $49,141.00. Following the sale, the director directly owned 250 shares in the company, valued at $39,250. This trade represents a 55.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Palvella Therapeutics Price Performance

PVLA stock traded up $1.77 during trading on Friday, reaching $157.24. 162,218 shares of the company were exchanged, compared to its average volume of 265,893. The company has a market capitalization of $2.27 billion, a price-to-earnings ratio of -32.55 and a beta of -0.25. The company has a 50-day moving average of $148.17 and a two-hundred day moving average of $129.27. Palvella Therapeutics, Inc. has a twelve month low of $52.36 and a twelve month high of $161.38.

Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported ($1.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.35). On average, analysts forecast that Palvella Therapeutics, Inc. will post -6.36 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on PVLA. Canaccord Genuity Group set a $232.00 price objective on Palvella Therapeutics in a report on Wednesday, August 5th. Truist Financial set a $207.00 target price on Palvella Therapeutics in a research report on Wednesday, August 5th. Chardan Capital raised Palvella Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 28th. HC Wainwright restated a “buy” rating and set a $270.00 price target on shares of Palvella Therapeutics in a report on Wednesday, July 22nd. Finally, Stephens reaffirmed an “overweight” rating and issued a $220.00 price objective on shares of Palvella Therapeutics in a research note on Thursday, May 21st. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Palvella Therapeutics has an average rating of “Buy” and an average price target of $209.14.

Read Our Latest Report on Palvella Therapeutics

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of PVLA. KBC Group NV acquired a new position in Palvella Therapeutics during the 1st quarter worth about $28,000. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Palvella Therapeutics in the second quarter valued at about $35,000. Group One Trading LLC increased its stake in shares of Palvella Therapeutics by 151.5% in the fourth quarter. Group One Trading LLC now owns 332 shares of the company’s stock valued at $35,000 after buying an additional 200 shares during the period. Russell Investments Group Ltd. bought a new position in shares of Palvella Therapeutics during the third quarter worth about $36,000. Finally, Archer Investment Corp bought a new position in shares of Palvella Therapeutics during the second quarter worth about $69,000. 40.11% of the stock is owned by institutional investors.

About Palvella Therapeutics

(Get Free Report)

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.

Read More